Mosaic Biosciences Adds Carterra HT-SPR Platform to Accelerate Biologics Discovery

Published: March 26, 2026 | Category: News, Technology, Biologics Discovery

---

Mosaic Biosciences has expanded its discovery capabilities with the addition of the Carterra® LSAXT high-throughput surface plasmon resonance (HT-SPR) instrument, one of the most advanced label-free characterization platforms available to biologics discovery teams today.

This strategic investment deepens Mosaic’s ability to deliver high-quality, developable antibody and protein therapeutic candidates for biopharma and biotech partners, faster and with greater mechanistic precision than ever before.

---

What Is High-Throughput SPR and Why Does It Matter for Biologics Discovery?

Surface plasmon resonance (SPR) is the gold standard for characterizing how biologics, antibodies, proteins, and other large molecules bind to their targets. Unlike traditional assays, SPR measures binding in real time and label-free, providing kinetic data (how fast molecules bind and unbind) that directly predicts therapeutic efficacy and developability.

The challenge with conventional SPR has always been throughput. Traditional platforms process candidates one at a time, creating a bottleneck during lead identification and optimization, the phases where speed matters most.

Carterra’s HT-SPR technology solves this bottleneck. The Carterra LSAXT platform uses patented microfluidics to deliver real-time kinetic analysis across large candidate libraries simultaneously, enabling teams to generate significantly more high-quality binding data in a fraction of the time and sample volume required by legacy platforms.

For Mosaic’s partners, this translates directly to faster timelines and more confident candidate selection.

---

How Mosaic Is Integrating the Carterra Platform

The Carterra LSAXT is being incorporated into Mosaic’s discovery pipelines immediately across three core workflows:

High-throughput kinetic measurements. Mosaic can now profile binding kinetics, on-rate, off-rate, and affinity, across extensive candidate libraries in a single run. This enables rapid triage of large panels and surfaces, the highest-potential candidates early in the discovery process.

Epitope binning. The platform enables simultaneous competition-based epitope mapping, allowing Mosaic to group candidates by their binding sites on a target and prioritize those with the highest functional relevance. This is especially powerful for programs targeting complex antigens or requiring non-overlapping epitope coverage, such as bispecific or combination strategies.

Computational modeling integration. Rich biophysical data from HT-SPR feeds directly into Mosaic’s computational decision frameworks, enabling more predictive modeling and better-informed go/no-go decisions before investing in downstream development.

Together, these capabilities compress the timeline between initial discovery and candidate nomination, a critical advantage in competitive therapeutic areas.

---

Strengthening Discovery Across Oncology, Immunology, and Rare Disease

Mosaic’s therapeutic focus spans oncology, immunology, and rare diseases, all areas where the complexity of target biology demands deep mechanistic characterization early in discovery. With HT-SPR integrated into the discovery engine, Mosaic can apply rigorous binding characterization at a scale that was previously impractical.

“As we scale our antibody and protein discovery engine, this acquisition reinforces Mosaic’s commitment to delivering high-quality therapeutic candidates faster and with deeper mechanistic insight,” said Tracey Mullen, Chief Strategy Officer at Mosaic Biosciences. “The Carterra platform’s ability to generate rich binding data at scale, including best-in-class kinetics, and epitope binning directly complements our integrated engineering and discovery strategy.”

---

What This Means for Mosaic’s Partners

For biotech and biopharma companies working with Mosaic, the addition of the Carterra LSAXT platform means:

• Earlier confidence in lead selection — kinetic and epitope data available sooner in the campaign, not just at the end
• Reduced downstream risk — better data at the front end means fewer surprises in IND-enabling studies
• More efficient use of resources — high-throughput workflows mean more ground covered without proportional increases in sample consumption or timelines
• Deeper integration with Mosaic’s engineering capabilities — SPR data feeds directly into the same computational and engineering frameworks that power Mosaic’s multispecific and optimization programs

---

About Mosaic Biosciences

Mosaic Biosciences is a biologics discovery company specializing in antibody and protein engineering, with expertise spanning transgenic mouse platforms, display technologies, and multispecific antibody formats. Mosaic partners with biotech and pharmaceutical companies to generate high-quality, developable biologics optimized for real-world therapeutic success.

To learn more about our discovery capabilities or explore a partnership, contact us.

---

Read the full press release: [Mosaic Biosciences Expands Discovery Capabilities with Carterra® High-Throughput SPR Platform]

---

Tags: antibody discovery, biologics CRO, surface plasmon resonance, HT-SPR, Carterra, epitope binning, kinetics, drug discovery, oncology, immunology, rare disease, lead optimization, protein engineering